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The Journal of Immunology
Imatinib Triggers Phagolysosome Acidification and
Antimicrobial Activity against Mycobacterium bovis Bacille
Calmette–Gue´rin in Glucocorticoid-Treated Human
Macrophages
Julia Steiger,* Alexander Stephan,* Megan S. Inkeles,† Susan Realegeno,‡
Heiko Bruns,x Philipp Kro¨ll,* Juliana de Castro Kroner,*,{ Andrea Sommer,*,{
Marina Batinica,* Lena Pitzler,‖ Rainer Kalscheuer,# Pia Hartmann,**,††
Georg Plum,†† Steffen Stenger,‡‡ Matteo Pellegrini,† Bent Brachvogel,‖,xx
Robert L. Modlin,‡,{{ and Mario Fabri*,{
Glucocorticoids are extensively used to treat inflammatory diseases; however, their chronic intake increases the risk for mycobac-
terial infections. Meanwhile, the effects of glucocorticoids on innate host responses are incompletely understood. In this study, we
investigated the direct effects of glucocorticoids on antimycobacterial host defense in primary human macrophages. We found that
glucocorticoids triggered the expression of cathelicidin, an antimicrobial critical for antimycobacterial responses, independent of
the intracellular vitamin D metabolism. Despite upregulating cathelicidin, glucocorticoids failed to promote macrophage antimy-
cobacterial activity. Gene expression profiles of human macrophages treated with glucocorticoids and/or IFN-g, which promotes
induction of cathelicidin, as well as antimycobacterial activity, were investigated. Using weighted gene coexpression network
analysis, we identified a module of highly connected genes that was strongly inversely correlated with glucocorticoid treatment and
associated with IFN-g stimulation. This module was linked to the biological functions autophagy, phagosome maturation, and lytic
vacuole/lysosome, and contained the vacuolar H+-ATPase subunit a3, alias TCIRG1, a known antimycobacterial host defense
gene, as a top hub gene. We next found that glucocorticoids, in contrast with IFN-g, failed to trigger expression and phagolyso-
some recruitment of TCIRG1, as well as to promote lysosome acidification. Finally, we demonstrated that the tyrosine kinase
inhibitor imatinib induces lysosome acidification and antimicrobial activity in glucocorticoid-treated macrophages without re-
versing the anti-inflammatory effects of glucocorticoids. Taken together, we provide evidence that the induction of cathelicidin by
glucocorticoids is not sufficient for macrophage antimicrobial activity, and identify the vacuolar H+-ATPase as a potential target
for host-directed therapy in the context of glucocorticoid therapy. The Journal of Immunology, 2016, 197: 222–232.
G
lucocorticoids have been widely used for decades as
potent immunosuppressive drugs to treat human in-
flammatory diseases (1). However, long-term glucocor-
ticoid therapy, for instance, in patients suffering from rheumatoid
arthritis, constitutes a risk factor for developing active tuberculosis
(TB) (2) and other mycobacterial infections (3). Meanwhile, the
effects of glucocorticoids on innate host responses are incom-
pletely understood. Despite obvious anti-inflammatory effects,
emerging evidence suggests that glucocorticoids also enhance
innate immune pathways, for instance, the NLRP3 inflammasome
(4). Consistent with this idea, recent microarray transcriptional
profiling revealed that long-term exposure of human macrophages
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to glucocorticoids strengthened components of the innate re-
sponse, albeit weakening an acquired immune signature (5).
Human macrophages play a central role in the host defense
against mycobacteria, because they are the natural niches for these
intracellular pathogens. We have contributed to the understanding
of how human macrophages kill mycobacteria by identifying a
vitamin D–dependent host defense pathway (6–8). The vitamin D
antimicrobial pathway is induced by innate and acquired immune
signals, including TLR2/1 ligand, CD40L, and IFN-g (6–9).
Central early events include the induction of IL-32 and IL-15 (10,
11), the CYP27b1-hydroxylase, which converts 25-OH vitamin D
(25D) into the active form 1,25-di-OH vitamin D (1,25D) in
an autocrine manner, as well as the upregulation of the vita-
min D receptor (VDR) (6–9). Subsequently, 1,25D triggers VDR-
mediated induction of cathelicidin antimicrobial peptide (12,
13), pivotal for killing mycobacteria in phagolysosomes (14).
Furthermore, this pathway involves the vitamin D–dependent
induction of autophagy, which is important to overcome the
phagosome maturation block (7, 15, 16), an important myco-
bacterial virulence strategy (17–22). Given the importance of
macrophages in combating mycobacteria, we investigated the
impact of glucocorticoids on the antimycobacterial response in
primary human macrophages.
Materials and Methods
Reagents
Recombinant human M-CSF was purchased from Miltenyi Biotec and
recombinant human IFN-g from Becton Dickinson. M-CSF was used at a
concentration of 50 ng/ml and IFN-g at a concentration of 10 ng/ml.
Dexamethasone, hydrocortisone, imatinib mesylate, and mifepristone
were from Sigma-Aldrich and used at the following concentrations:
dexamethasone 10–1000 nM, hydrocortisone 300 nM, imatinib mesylate
5–10 mM, and mifepristone 1 mM. 25D3 and 1,25D3 were obtained from
Biomol and used as indicated. Bafilomycin A1 was purchased from Sigma-
Aldrich and Invivogen and used at 100 nM. The mAbs used were: anti–IL-
15 PE (clone 34559) and IgG1 PE isotype control (clone 11711) from
R&D Systems; anti-LAMP1 (clone D2D11) from Cell Signaling; anti-
LAMP1 (clone eBioH4A3) from eBioscience; IgG1 pure isotype control
(clone X40) and IgG2a isotype control (clone X39) from Becton Dick-
inson; anti-cathelicidin (clone OSX12) from Abcam or Novus Biologicals;
and monoclonal anti-TCIRG1 from Abcam. Anti-mouse IgG1 PE (clone
A85-1) and anti-mouse IgG2a FITC (clone R19-15) were obtained from
Becton Dickinson. LysoSensor Green DND-189, DAPI, and secondary
Abs labeled with Alexa Fluor 488 or Alexa Fluor 594 were purchased from
Life Technologies. FCS and human AB serum were purchased from PAA
Laboratories and PAN Biotech. RPMI 1640 and macrophage serum-free
media (SFM) were obtained from Life Technologies.
Ethics statement
This study was conducted according to the principles expressed in the
Declaration of Helsinki. The study was approved by the local Ethics
Committee (Ethikkommission) of the University of Cologne, Germany. All
donors provided written informed consent for the collection of peripheral
blood and subsequent analyses.
Cell preparations and macrophage culture
Whole blood or buffy coats from healthy donors or patients on long-
term glucocorticoid therapy were obtained with informed consent. Patients
were receiving dosages of prednisolone between 7.5 and 45 mg/d for
at least 4 wk for treatment of chronic inflammatory diseases. Their
clinical diagnoses were pyoderma gangrenosum, polymyalgia rheu-
matica, psoriatic arthritis, and pyoderma gangrenosum, respectively.
PBMCs were isolated by Ficoll-Paque (GE Healthcare). Monocytes were
isolated via CD14+ MACS cell separation (Miltenyi Biotec) according
to the manufacturer’s instructions. Monocyte-derived macrophages
(MDMs) were prepared by culturing peripheral blood monocytes in
RPMI 1640 media containing 10% FCS for 4–7 d in the presence of
M-CSF (50 ng/ml). Afterward cells were cultured in fresh media with
10% vitamin D–sufficient human AB serum (supplemented with 25D3 to
reach 25D serum levels between 100 and 180 nmol/l) unless indicated
otherwise.
Real-time quantitative PCR
mRNAwas isolated from MDMs or monocytes using the RNeasy mini kit
(Qiagen) according to the manufacturer’s recommended protocol. cDNA
was prepared using iScript cDNA Synthesis kit (BioRad), and mRNA
levels were assessed by quantitative PCR using Power SYBR Green
Master Mix (Life Technologies) as previously described (7) and GoTaq
qPCR Master Mix (Promega) according to the manufacturer’s recom-
mended protocol. Primer sequences for human CYP27B1, cathelicidin,
CYP24A1, IL-15, VDR, TCIRG1 (vacuolar H+-ATPase [v-ATPase] V0
subunit a3) and h36B4 were previously reported (6, 7, 23). Primer se-
quences for human TNF-a were: TNF-a forward, 59-GGAGAAGGGT-
GACCGACTCA-39, TNF-a reverse, 59-CTGCCCAGACTCGGCAA-39.
Human IL-1b, IL-10, IL-32, and DRAM1 Quantitect Primer Assays were
from Life Technologies.
Gene expression profiling
Total RNA of cells was isolated with TRIzol (Life Technologies), and
RNA quality was confirmed using microcapillary electrophoresis (2100
Bioanalyzer; Agilent). A total of 100 ng RNA was labeled and hybridized
to Sureprint G3 human GE 8x60K whole genome mRNA microarray
according to the manufacturer’s specifications. The arrays were scanned
(Agilent G2595C scanner), and data were extracted and processed using
the Genespring XII software (Agilent). Macrophage gene expression files
containing array data are available under accession no. GSE79077 in the
Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/).
Weighted gene coexpression network analysis (WGCNA) was performed
on the microarray data set to identify networks of correlated genes using
the R library ‘wgcna’ (22). Gene modules were generated using the
function blockwiseModules(), with a soft thresholding power of 12.
Module eigengenes (MEs), defined as the first principal component of each
gene module, were correlated to experimental treatments of media, IFN-g,
dexamethasone, and IFN-g/dexamethasone. Correlation was calculated
using a binary matrix representation where a particular sample had a value
of 1 for the treatment used and 0 for all other treatments. Correlations and
corresponding p values were displayed in a heat map using the labeled-
Heatmap() function. For each module, hub genes, or genes with high
intermodular connectivity, were identified using the signedKME() func-
tion. Functional gene annotation enrichment analysis was done using In-
genuity Pathways Analysis (IPA) (http://www.ingenuity.com) or Cytoscape
v3.2.0 software with ClueGO v2.1.5 plugin (PMID: 19237447). Functional
annotation network was then generated with Gephi v0.8.2 b (24).
Flow cytometry
Surface staining with IL-15 PE or the appropriate isotype control was
performed in PBS containing 20% FCS and 0.1% sodium azide. For in-
tracellular measurement of cathelicidin and TCIRG1, cells were stained
using Cytofix/Cytoperm kit (Becton Dickinson) according to the manu-
facturer’s recommended instructions. For acidification assays, MDMs or
monocytes were incubated with LysoSensor Green (1–2 or 1 mM, re-
spectively) for 30 min and subsequently washed with PBS. Flow cytometry
was conducted on a FACSCalibur (BD Biosciences), and data were ana-
lyzed using FlowJo software (Tree Star). MDM and monocyte gates were
set based on forward and sideward scatters.
Infection of MDMs, treatment with stimuli, and quantification
of mycobacterial growth
Mycobacterium bovis Bacille Calmette–Gue´rin strain Pasteur (BCG) was
grown in suspension with constant, gentle rotation at 37˚C in 7H9 media
containing Difco Middlebrook 7H9 broth supplemented with 0.5% glyc-
erol, 0.05% tyloxapol, and 10% BBL Middlebrook OADC Enrichment.
MDMs were infected for 3–4 h with single-cell suspensions of BCG at a
multiplicity of infection of three to five in a 24-well plate. Afterward ex-
tracellular bacteria were removed by vigorous washing. For CFU assays,
MDMs were treated with dexamethasone or IFN-g and incubated for 3 d.
To determine the number of viable intracellular bacilli, cells were lysed
with 0.05% SDS (Serva Electrophoresis). Lysates of infected cells were
resuspended vigorously and diluted in 0.05% tyloxapol (Sigma-Aldrich).
Four to five dilutions of each sample were plated on 7H10 agar plates
(Becton Dickinson and Merck Millipore) and incubated for 21 d at 37˚C.
Immunostaining for TCIRG1 and LAMP1
For intracellular staining of TCIRG1 and LAMP1, MDMs were grown on
eight-well chamber slides (Becton Dickinson) and stimulated with dexa-
methasone or IFN-g, or left untreated for 20 h. Cells were fixed with
methanol and permeabilized with saponin (0.01%) and Triton X-100
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(0.1%). Next, cells were stained with mAbs against TCIRG1 and LAMP1,
detected with anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 594,
and costained with DAPI. In some experiments, MDMs were infected for
3 h with single-cell suspensions of BCG. Cells were analyzed with a
Keyence BZ-9000 microscope. For quantification of TCIRG1bright cells,
counts from three independent investigators of ∼50 cells (uninfected
MDMs) or 200 cells (infected MDMs) per condition were averaged. To
quantify lysosomes that recruited TCIRG1, three to five image sections of
∼50 cells (uninfected MDMs) or 200 cells (infected cells) per condition
were analyzed by calculating the Manders overlap coefficient (M2 =
fraction of LAMP1 overlapping TCIRG1) using ImageJ with JACoP plu-
gin. Identical threshold settings were applied to every condition.
Confocal microscopy
MDMs were grown on eight-well chamber slides (Becton Dickinson) and
infected for 3 h with single-cell suspensions of M. bovis BCG Pasteur
(pMV261::dsRed) expressing dsRed2 fluorescent protein under control of
the constitutive Hsp60 promoter. Next, MDMs were stimulated with
dexamethasone or IFN-g, or left untreated for 20 h. In some experiments,
cells were fixed with methanol and permeabilized with saponin (0.01%)
and Triton X-100 (0.1%). Infected MDMs were stained with mouse mAb
against TCIRG1, followed by anti-mouse Alexa Fluor 488 and DAPI. In
some experiments, cells were fixed with paraformaldehyde (4%) and
permeabilized with saponin (0.2%). Infected MDMs were stained with
mouse mAb against cathelicidin, followed by anti-mouse Alexa Fluor 488
and DAPI. Cells were analyzed on an Olympus FV1000 confocal micro-
scope. For quantification of TCIRG1 recruitment to intracellular BCG/
clusters of BCG, counts from three independent investigators of ∼150
infected cells per condition were averaged. In addition, ∼20 image sections
of ∼150 cells were analyzed by calculating the Manders overlap coefficient
(M2 = fraction of LAMP1 overlapping TCIRG1) using ImageJ with JACoP
plugin. Identical threshold settings were applied to every condition.
Statistics
The p values were calculated by two-tailed Student t tests in Fig. 8C.
Differences in all other quantitative PCR, FACS, and CFU data were an-
alyzed by Friedman test for k dependent samples to compare more than
two groups. If this test yielded significant results, we performed a Wil-
coxon test as a post hoc test to compare two groups. n refers to the number
of repeat experiments performed with cells from individual human donors.
Results
Dexamethasone promotes an anti-inflammatory macrophage
cytokine profile
Because the therapeutic benefits of glucocorticoids are funda-
mentally linked to glucocorticoid-mediated anti-inflammatory ef-
fects, we tested whether glucocorticoid treatment of primary
human macrophages results in a shift from a proinflammatory
toward an anti-inflammatory profile. Therefore, we compared
mRNA expression of key proinflammatory and anti-inflammatory
cytokines, specifically pro–IL-1b, TNF-a, and IL-10, in MDMs
cultured with dexamethasone, the inflammatory stimulus IFN-g,
or media alone for 20 h. We found that dexamethasone treatment
significantly inhibited the mRNA expression of pro–IL-1b and
TNF-a by 95 and 30%, respectively, when compared with the
media control (both p , 0.05; Fig. 1), whereas IFN-g induced
pro–IL-1b expression by 3.9-fold and TNF-a expression by 21-
fold (both p , 0.05; Fig. 1). Moreover, dexamethasone induced
IL-10 by 3.4-fold (p , 0.05; Fig. 1). IFN-g had no significant
effect on IL-10 gene expression. Taken together, these data con-
firm that dexamethasone promotes an anti-inflammatory macro-
phage cytokine profile.
Dexamethasone induces cathelicidin expression
Anti-inflammatory macrophage phenotypes have a reduced ca-
pacity to control intracellular infections. For instance, in mouse
macrophages, the expression of inducible NO synthase and
the production of NO (25–27), a fundamental murine anti-
mycobacterial molecule, are significantly reduced by glucocorti-
coids (28, 29). We and others previously reported that in humans,
but not in mice, the vitamin D–mediated induction of cathelicidin
antimicrobial peptide has a central role in the antimycobacterial
activity in macrophages (6, 7, 14, 30, 31). Thus, we compared the
ability of dexamethasone and IFN-g to induce cathelicidin. MDMs
were stimulated with dexamethasone, IFN-g, or media alone for
20 h, and expression of cathelicidin mRNA was measured.
Dexamethasone and IFN-g each induced cathelicidin mRNA ex-
pression by 3.1- and 2.9-fold as compared with media (both p ,
0.001; Fig. 2A). Furthermore, dexamethasone induction of cath-
elicidin gene expression was observed at 100 and 1000 nM, but
not at 10 nM (data not shown). Next, we tested whether cath-
elicidin induction was specific for dexamethasone or whether a
different member of the glucocorticoid family, hydrocortisone,
also induces cathelicidin gene expression. We found that hydro-
cortisone induced cathelicidin expression by 2.3-fold compared
with media (p , 0.05; Fig. 2B). Taken together, these data dem-
onstrate that glucocorticoids induce cathelicidin expression.
Dexamethasone induction of cathelicidin is independent of the
macrophage vitamin D defense pathway
The induction of cathelicidin by TLR2/1 ligand, IFN-g, or CD40L
is dependent on the bioavailability of 25D in the sera added to the
cultures, limiting the intracellular vitamin D metabolism in human
macrophages (6–8). Thus, we compared the ability of dexamethasone
FIGURE 1. Dexamethasone (Dexa) promotes an anti-inflammatory cy-
tokine profile in human macrophages. MDMs were stimulated with Dexa
(100 nM), IFN-g, or media alone for 20 h. Gene expression of pro–IL1-b
(n = 8), TNF-a (n = 5), and IL-10 (n = 8) was determined by quantitative
PCR (mean fold change 6 SEM). *p , 0.05.
FIGURE 2. Dexamethasone (Dexa) induces cathelicidin gene expres-
sion in human macrophages. (A) MDMs were stimulated with Dexa (100
nM), IFN-g, or media alone for 20 h. Cathelicidin gene expression was
assessed by quantitative PCR (mean fold change 6 SEM, n = 21). (B)
MDMs were stimulated with hydrocortisone (HC), IFN-g, or media alone
for 20 h. Gene expression of cathelicidin was assessed by quantitative PCR
(mean fold change 6 SEM, n = 5). *p , 0.05, **p , 0.01, ***p , 0.001.
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and IFN-g to regulate key components of the vitamin D defense
pathway in macrophages. Dexamethasone had no effect on IL-15
mRNA (data not shown) and surface expression (Fig. 3A, 3B),
nor on IL-32 mRNA expression (Fig. 3C), early events of the
vitamin D defense pathway. In addition, dexamethasone sig-
nificantly suppressed expression of the CYP27B1-hydroxylase
by 56% and did not induce VDR mRNA expression (p , 0.001
and p , 0.01; Fig. 3D). As expected, IFN-g induced IL-15
mRNA (data not shown) and surface expression when com-
pared with media control (D mean fluorescence intensity [DMFI] =
11.4 versus 5.4, p , 0.01; Fig. 3A, 3B), as well as IL-32 (50-fold,
p , 0.05; Fig. 3C), CYP27B1 (17.0-fold, p , 0.001; Fig. 3D), and
VDR (2.5-fold, p , 0.001; Fig. 3D) mRNA expression. These
findings indicate that the glucocorticoid-mediated induction of
cathelicidin is not linked to the previously described induction of
the intracellular vitamin D defense pathway in human macro-
phages. Thus, we hypothesized that, in contrast with the 25D-
dependent IFN-g induction of cathelicidin, dexamethasone triggers
cathelicidin expression independently of serum 25D. Therefore, we
stimulated MDMs with dexamethasone, IFN-g, or media alone in
vitamin D–deficient human serum (25D serum level = 31 nmol/l).
The active form of vitamin D, 1,25D, was used as positive control.
1,25D and dexamethasone both induced cathelicidin (both p ,
0.05; Fig. 4A) as compared with media control, yet, as expected,
IFN-g failed to induce cathelicidin mRNA expression in 25D-
deficient culture conditions (Fig. 4A). CYP24, a classical genomic
target of vitamin D used as a control readout, was induced by
neither dexamethasone nor IFN-g in 25D-deficient conditions
(Fig. 4A). Given that the vitamin D–deficient serum used in these
assays still contains 31 nmol/l 25D, we next analyzed dexametha-
sone induction of cathelicidin in SFM, which does not contain
detectable amounts of 25D. Again, IFN-g failed to induce, whereas
dexamethasone and 1,25D were able to trigger, cathelicidin mRNA
expression by 5.3- and 21-fold, respectively (both p , 0.05;
Fig. 4B). CYP24 was induced by neither dexamethasone nor IFN-g
under these conditions.
Next, we analyzed whether dexamethasone induces expression of
cathelicidin protein. MDMs were stimulated with dexamethasone in
SFM for 20 h, and cathelicidin expression was measured by in-
tracellular FACS. Dexamethasone triggered protein expression of
cathelicidin in SFM (38.9 versus 5.1% positive cells in the media
control; Fig. 4C). Finally, cathelicidin induction by glucocorticoids
was dependent on the glucocorticoid receptor (GR), because mife-
pristone, a GR antagonist, completely blocked dexamethasone, but
not 1,25D-induced cathelicidin gene expression (Fig. 4D). Taken
together, these data showed that dexamethasone triggers cathelicidin
expression by a mechanism that is different from the previously
described IFN-g–induced vitamin D–dependent pathway. Gluco-
corticoid induction of cathelicidin was observed at concentrations of
dexamethasone (100 and 1000 nM), as well as of hydrocortisone
(300 nM), that are within the range of the serum levels in individuals
taking moderate-to-high therapeutic doses of glucocorticoids (32).
Dexamethasone fails to induce antimycobacterial activity
Cathelicidin is pivotal to the antimycobacterial response in human
macrophages and kills bacteria by directly binding bacterial mem-
branes (6, 7, 14–16). To investigate whether dexamethasone-induced
cathelicidin targets intracellular mycobacteria, we infected MDMs
with BCG (pMV261::dsRed) expressing dsRed2 fluorescent protein.
Afterward, infected cells were stimulated with either dexamethasone
or IFN-g for 20 h and stained with anti-cathelicidin mAb. Confocal
microscopy analysis showed colocalization of dexamethasone-
induced and IFN-g–induced cathelicidin with BCG (Supplemental
Fig. 1A). Because dexamethasone induced cathelicidin expression
and dexamethasone-induced cathelicidin colocalized with intracel-
lular BCG, we asked whether dexamethasone promotes anti-
mycobacterial activity in human macrophages. To test this, we
infected human MDMs from three individual donors with BCG and
treated the BCG-infected MDMs with dexamethasone and/or IFN-g,
or media alone. We measured between 50 and 73% bacterial growth
restriction in the IFN-g–treated MDMs as compared with media
control (Fig. 5). In contrast, we observed no reduction in intracellular
bacterial load in the dexamethasone-treated MDMs (Fig. 5). More-
over, we measured a similar bacterial growth pattern in the IFN-g
plus dexamethasone-treated cells as in the IFN-g–treated cells
(Fig. 5). IFN-g plus dexamethasone also resulted in a comparable
FIGURE 3. Dexamethasone (Dexa) dissociates
the vitamin D host defense pathway. (A and B)
MDMs were stimulated with Dexa (100 nM), IFN-g,
or media alone for 20 h. IL-15 surface expression
was determined by FACS analyses. (A) Histogram
plots from 1 representative donor out of 12 (DMFI).
(B) Summary of 12 donors (DMFI 6 SEM). (C)
Gene expression for IL-32 (n = 6), (D) CYP27B1
(n = 17), and VDR (n = 18) was determined by
quantitative PCR (mean fold change 6 SEM). *p ,
0.05, **p , 0.01, ***p , 0.001.
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induction of cathelicidin gene expression as IFN-g alone
(Supplemental Fig. 1). Taken together, our data show that dexa-
methasone induces cathelicidin antimicrobial peptide expression
but fails to promote antimicrobial activity against intracellular
mycobacteria in human macrophages.
Identification of a macrophage host defense network associated
with IFN-g and inversely correlated with dexamethasone
stimulation
The finding that dexamethasone triggers cathelicidin expression, yet
fails to induce antimicrobial activity, suggested that dexamethasone
does not induce or dexamethasone suppresses other critical factors
involved in the macrophage antimycobacterial host response. To
further investigate dexamethasone-regulated macrophage programs,
we performed whole genomemicroarrays. Therefore, MDMs were
cultured with dexamethasone and/or IFN-g, or media alone. To
uncover networks of highly interconnected genes, we subjected
the microarray data to WGCNA, a systems biology approach. In
brief, this analysis uses pairwise gene correlations, which are
weighted to favor more robust coexpression values, to group
genes into modules. MEs were calculated that represented a theo-
retical average gene for each module. Enrichment for particular
modules in each treatment group was calculated by correlating
MEs to experimental conditions (Fig. 6A). This approach identified a
green module of 620 genes, which was significantly associated with
IFN-g stimulation and the most inversely correlated module to
dexamethasone treatment. ClueGO functional enrichment analyses
showed that the green module was significantly linked to key
functional pathways in antimicrobial host defense, including
lytic vacuole/lysosome, latent infection (Mycobacterium tuberculosis),
phagosome maturation (early endosomal stage), and defense response
(Fig. 6B, 6C). Among the genes in this module are several v-ATPase
subunits, such as TCIRG1 alias v-ATPase V0 subunit a3, ATP6V1C1,
ATP6V1H, and ATP6V0E1, which are involved in acidification of
lysosomes; DRAM1, which promotes autophagic defense against
mycobacteria (33); and VPS18, linked to autophagolysosome fusion.
FIGURE 4. Dexamethasone (Dexa) induces cathelicidin independent of serum 25D in human macrophages. (A and B) MDMs were stimulated for 20 h
either in (A) serum with 10% 25D-deficient human serum (25D serum level = 31 nmol/l) or (B) SFM with Dexa (100 nM), IFN-g, 1,25D (10 nM), or media
alone. Gene expression of cathelicidin and CYP24A1 was assessed by quantitative PCR [mean fold change6 SEM; (A), n = 5, (B), n = 6]. (C) MDMs were
stimulated for 20 h in SFM with Dexa (1000 nM) or media alone. Intracellular cathelicidin protein expression was determined by FACS analyses
(% cathelicidin-positive cells). (D) MDMs were stimulated for 20 h in SFM with either mifepristone (Mife; 1 mM), Dexa (1000 nM), 1,25D (10 nM), or
media alone as indicated. Cathelicidin gene expression was determined by quantitative PCR (mean fold change 6 SEM, n = 5). *p , 0.05.
FIGURE 5. Dexamethasone (Dexa) fails to induce antimycobacterial
activity in human macrophages. MDMs were infected with BCG for 3–4 h
before stimulation with Dexa (100 nM), IFN-g, both in combination, or
media alone for 3 d. Viable bacteria were quantified by CFU assay on day
3. Percentage antimicrobial activity relative to media (left panel) and CFU
counts (right panel) are shown. Each colored row represents data obtained
with MDMs from one individual donor (n = 3).
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Several genes (CYBB, IFI6, PRKCD, SOCS3, SPI1) for IFN-g sig-
naling and TNF were also connected to this module. Taken together,
our analyses revealed a network of host defense genes connected to
phagosome maturation and the lysosome, fundamental aspects of the
antimycobacterial host defense, which is associated with IFN-g but
not glucocorticoid treatment.
IFN-g, yet not dexamethasone, induces TCIRG1 expression
and phagolysosome recruitment, as well as lysosome
acidification
The host defense genes in the green module identified by the ClueGO
functional group analyses were next ranked according to their kME
values (Fig. 6C), revealing TCIRG1 (kME = 0.98) as the top hub
gene, which is the most connected gene. We and others previously
showed that induction and lysosomal recruitment of TCIRG1 is
linked to lysosome acidification, a hallmark of phagolysosome
maturation, and subsequent antimycobacterial activity in human
macrophages (23, 34), prompting us to study TCIRG1 in more de-
tail. First, we measured TCIRG1 mRNA expression using quanti-
tative PCR, demonstrating that dexamethasone suppressed TCIRG1
mRNA expression by 33% compared with media in MDMs after
20 h (p , 0.01; Fig. 7A). In contrast, IFN-g triggered TCIRG1
mRNA expression by 2.1-fold when compared with media (p ,
0.01; Fig. 7A). Similar results were observed in BCG-infected
FIGURE 6. Identification of a macrophage host defense
network inversely correlated with dexamethasone (Dexa) treat-
ment and associated with IFN-g stimulation. WGCNA analysis
of MDMs stimulated with Dexa (100 nM) and/or IFN-g or
cultured in media alone for 20 h. (A) Heat map depicting
correlation of ME to treatment condition with corresponding
p values. Each row is labeled with a color corresponding to an
individual module from the WGCNA analysis, and the num-
ber of probe sets per module is given after the color. Red
indicates positive correlation; green indicates inverse corre-
lation. (B and C) Association of the WGCNA green module to
ClueGO functional groups lytic vacuole/lysosome, latent in-
fection (M. tuberculosis), phagosome maturation (early endosomal
stage), defense response, and IFN-g signaling. (B) The p
values of associations to ClueGO functional groups are
displayed. (C) Functional annotation network of ClueGO
analysis generated by Gephi. Red circle sizes increase with
ClueGO analysis increasing p value; green circle sizes increase
with WGCNA increasing eigengene-based connectivity (kME)
values.
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macrophages (Supplemental Fig. 2A). Next, we investigated the
effect of dexamethasone and IFN-g on TCIRG1 protein expression.
MDMs were stimulated with dexamethasone, IFN-g, or media alone
for 20 h, and TCIRG1 expression was measured by intracellular
FACS. IFN-g induced protein expression of TCIRG1 (78.6 versus
31.2% in the media control; Fig. 7B), whereas dexamethasone had
no effect on TCIRG1 expression compared with media (Fig. 7B).
Using immunofluorescence microscopy, we analyzed the expres-
sion of TCIRG1 and its lysosomal recruitment. IFN-g upregulated
TCIRG1 expression and induced TCIRG1 recruitment to lysosomes
in both uninfected (Fig. 7C, 7D) and BCG-infected macrophages
(Supplemental Fig. 2B, 2C). In contrast, dexamethasone failed to
induce TCIRG1 expression and lysosome recruitment in uninfected
(Fig. 7C, 7D) and BCG-infected macrophages (Supplemental Fig.
2B, 7C).
To investigate whether TCIRG1 is recruited to the mycobacteria-
containing vacuoles, we infected MDMs with BCG (pMV261::
dsRed). Afterward, infected cells were stimulated with dexa-
methasone, IFN-g, or media alone for 20 h and stained with
anti-TCIRG1 mAb. Confocal microscopy analysis showed en-
hanced recruitment of TCIRG1 to intracellular BCG (pMV261::
dsRed) in IFN-g– but not in dexamethasone-treated cells (Fig.
7E, 7F).
Next, we tested the ability of dexamethasone and IFN-g to
regulate lysosome acidification. MDMs were stimulated with
dexamethasone, IFN-g, or media alone for 20 h, and acidification
was measured by FACS using LysoSensor Green pH indicator.
IFN-g stimulation resulted in an increase of LysoSensor-positive
cells (48.3 versus 4.91%; Fig. 7G), whereas dexamethasone had
no effect (2.14 versus 4.91%; Fig. 7G). Furthermore, Bafilomycin
A1, a specific inhibitor of v-ATPase, entirely reverted the IFN-g–
mediated induction of lysosome acidification (0.86 versus 48.3%;
Fig. 7G), indicating that IFN-g–mediated lysosome acidification
was dependent on a functional v-ATPase. Together, our data
showed that IFN-g triggers but dexamethasone fails to induce
TCIRG1 expression, recruitment to phagolysosomes, and induc-
tion of lysosome acidification in human macrophages.
We and others previously reported that the induction of auto-
phagy is a central mechanism by which IFN-g induced phagosome
maturation and lysosome acidification (7, 8, 35, 36). Moreover, a
recent study showed that glucocorticoids failed to induce auto-
phagy in M. tuberculosis–infected macrophages (37). In line with
these findings, IPA revealed a highly significant association of the
green module with the biological function autophagy (p , 1028;
Supplemental Fig. 3A). Among the genes associated with the IPA
biofunctional category autophagy were five genes also associated
with the lytic vacuole/lysosome: APC2, DRAM1, CTSL, VPS18,
and VTI1B, of which DRAM1 had the highest kME (DRAM1
kME = 0.95; Supplemental Fig. 3B). DRAM1 mRNA induction
can be used to monitor induction of autophagy (38). We found that
FIGURE 7. IFN-g triggers but dexamethasone
(Dexa) fails to induce TCIRG1 expression, phag-
olysosome recruitment, and lysosome acidification
in human macrophages. (A–C) MDMs were stim-
ulated with Dexa (100 nM), IFN-g, or media alone
for 20 h. (A) Gene expression of TCIRG1 was
assessed by quantitative PCR (mean fold change 6
SEM, n = 12). (B) Intracellular TCIRG1 protein
expression was determined by FACS analyses (%
TCIRG1+ cells). (C) MDMs were fixed and immu-
nostained with anti-TCIRG1 and anti-LAMP1. Orig-
inal magnification340. (D) Quantification of (C). Left
panel, Percentage of TCIRG1bright cells. Right panel,
Manders overlap coefficient M2 (fraction of LAMP1
overlapping TCIRG1). (E) MDMs were infected with
BCG (pMV261::dsRed) for 3 h and stimulated with
Dexa (100 nM), IFN-g, or media alone for 20 h,
fixed, immunostained with anti-TCIRG1, and ana-
lyzed by confocal microscopy. Image brightness was
enhanced equally across the entire image per journal
policy. (F) Quantification of (E). Left panel, Per-
centage of BCG/BCG clusters with TCIRG1 re-
cruitment. Right panel, Manders overlap coefficient
M2 (fraction of BCG overlapping TCIRG1). (G)
MDMs were stimulated with Dexa (100 nM), IFN-g,
IFN-g and Bafilomycin A1 in combination, or media
alone for 20 h and stained with LysoSensor Green.
Acidification was determined by FACS analyses (%
LysoSensor-positive cells). **p , 0.01.
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dexamethasone inhibited DRAM1 mRNA expression by 58%
(p , 0.05; Supplemental Fig. 3C), whereas IFN-g triggered
DRAM1 mRNA expression by 4.3-fold (p , 0.05; Supplemental
Fig. 3C) as measured by quantitative PCR. The induction of
DRAM1 mRNA expression and the association of the green
module to autophagy supported the known role of autophagy
in the IFN-g–mediated phagosome maturation and lysosome
acidification (7, 8, 35, 36), which we further investigated.
Macrophages were activated with IFN-g in the absence or
presence of two inhibitors of autophagy, specifically 3-MA
and Wortmannin, both of which blocked induction of lysosome
acidification by IFN-g (Supplemental Fig. 3D), supporting the
pivotal role of autophagy in promoting lysosome acidification
(7, 8, 35, 36).
Imatinib induces antimicrobial activity but has no effect on
inflammatory cytokine patterns in dexamethasone-treated
macrophages
The tyrosine kinase inhibitor imatinib has emerged as a host-
directed therapy for TB and other infections (23, 39, 40). In human
macrophages imatinib was shown to induce the v-ATPase,
leading to lysosome acidification and antimicrobial activity
against M. tuberculosis (23). This prompted us to investigate
whether imatinib can trigger lysosome acidification in dexamethasone-
treated human macrophages. We found that imatinib alone and
in combination with dexamethasone promoted lysosome acidi-
fication (10.8 and 15.5% LysoSensor-positive cells versus 1.4%
in the media control, both p , 0.05; Fig. 8A, 8B). The ability to
promote lysosome acidification was next tested in monocytic
cells from patients on long-term glucocorticoid therapy. We
decided to use monocytes directly isolated from blood, instead
of MDMs, for this experiment to avoid decline of glucocorti-
coid effects during the in vitro differentiation period. Of rele-
vance for this model we showed that IFN-g induced, yet
dexamethasone failed to trigger TCIRG1 and DRAM1 mRNA
expression, as well as lysosome acidification in monocytes
from healthy donors (Supplemental Fig. 4A, 4B). We cultured
blood-derived monocytes of four patients receiving long-term
glucocorticoid therapy for pyoderma gangrenosum, polymyalgia
rheumatica, psoriatic arthritis, and pyoderma gangrenosum,
respectively, with imatinib or media alone for 20 h. Imatinib
stimulation increased the number of LysoSensor-positive cells
when compared with media as measured in patient monocytes
by FACS (30.1% LysoSensor-positive cells versus 6.0% in
the media control, p , 0.01; Fig. 8C, Supplemental Fig. 4C).
Next, we investigated whether imatinib promotes anti-
mycobacterial activity in dexamethasone-treated MDMs and
found that imatinib alone and in combination with dexa-
methasone induced mycobacterial growth restriction by 69
and 64%, respectively, as compared with media control (both
p , 0.05; Fig. 8D), whereas dexamethasone alone failed
to induce antimicrobial activity (Fig. 8D). Imatinib had
no effect on the dexamethasone induction of cathelicidin
(Fig. 8E).
Given that the therapeutic benefits of glucocorticoids are fun-
damentally linked to glucocorticoid-mediated anti-inflammatory
effects, we tested whether imatinib modifies the dexamethasone-
induced anti-inflammatory cytokine profile in human mac-
rophages. We found that imatinib treatment did not reverse
dexamethasone-mediated suppression of baseline pro–IL-1b and
TNF-a expression, as well as induction of IL-10 expression as
compared with the media control (Fig. 8F). Taken together, these
data showed that imatinib promotes lysosome acidification and
antimicrobial activity in glucocorticoid-treated macrophages,
without reversing the anti-inflammatory properties of glucocorti-
coids.
Discussion
In this study, we provide evidence that glucocorticoids induce
cathelicidin in human macrophages. However, glucocorticoid in-
duction of cathelicidin occurs independently of autophagy, phag-
osome maturation, and lysosome acidification, known to be cru-
cial for host defense (6–8, 35, 36). Thus, although critical (6, 7,
14–16), the induction of cathelicidin is not sufficient to promote
antimycobacterial host defense. Nevertheless, we found that
imatinib promotes lysosome acidification and antimycobacterial
activity in glucocorticoid-stimulated macrophages. Strikingly,
imatinib did not reverse the anti-inflammatory effects of gluco-
corticoids, thereby suggesting a preventive and therapeutic po-
tential of imatinib in the context of glucocorticoid therapy.
A key finding of our study was the discovery of a glucocorticoid-
repressed and IFN-g–induced host defense network linked to
phagosome maturation and lytic vacuole/lysosome, which we
identified the v-ATPase subunit a3 TCIRG1 as a top hub gene. A
central role for the v-ATPase V0 in the host response to myco-
bacterial infections was suggested by Russell and colleagues (41),
who demonstrated that the v-ATPase V0 is excluded from the
nascent mycobacteria phagosome. In this study we found that
IFN-g induces TCIRG1 expression (42), its recruitment to
bacterial-loaded vacuoles, and promoted lysosome acidification
(23, 43–45). We previously reported that TCIRG1, in concert with
other subunits of the v-ATPase V0, was induced and recruited to
the mycobacterial phagolysosome by pharmacological activation
with imatinib, resulting in phagosome maturation and lysosome
acidification, and subsequent antimicrobial activity against
M. tuberculosis in human macrophages (23). The ability of ima-
tinib to trigger lysosome acidification in glucocorticoid-treated
macrophages identifies a strategy for augmenting antimicrobial
responses in the context of glucocorticoid treatment.
We observed that in dexamethasone-treated macrophages
cathelicidin colocalizes with intracellular mycobacteria. Therefore,
the crucial role of phagolysosome maturation and acidification in
the antimicrobial response could mean that cathelicidin-mediated
killing is pH dependent. Another, yet not mutually exclusive ex-
planation is that dexamethasone-induced cathelicidin is not effi-
ciently processed from its inactive precursor hCAP18 into the
active peptide LL-37. Despite the pivotal role of cathelicidin in the
macrophage host response, only few mechanisms involved in
regulating its expression are known. The human cathelicidin
promoter contains three vitamin D response elements, and 1,25D is
a direct inducer of cathelicidin (12, 13). Because physiological
1,25D serum levels are not sufficient to trigger the VDR-mediated
induction of cathelicidin, macrophages rely on the intracellular
conversion of 25D to 1,25D by the CYP27B1-hydroxylase. In fact,
described immune mechanisms resulting in upregulation of cath-
elicidin gene expression to date, including activation by TLR2/1
ligand and IFN-g, converge on the induction of CYP27B1 and the
conversion of 25D to 1,25D (6, 7). However, glucocorticoid in-
duction of cathelicidin was not linked to CYP27B1 induction, nor
was it dependent on serum 25D levels. Thus, glucocorticoid in-
duction of cathelicidin does not involve the previously described
vitamin D pathway. The detailed molecular mechanisms by which
glucocorticoids induce cathelicidin remain to be investigated.
One mechanism, by which glucocorticoids induce transcription,
is via GR binding to GR response elements on target genes. GR
response elements are found within the promoter, introns, or
exons of target genes (1). However, the human cathelicidin gene
does not contain GR binding sites based on the DNA consensus
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sequences 592GGTACAnnnTGTTCT-39 (46) and 59-AGAA-
CAnnnTGTTCT-39 (1). Notably, besides the vitamin D–mediated
induction, which is amplified by increased histone acetylation
(47), little is known about pathways activating cathelicidin. In
keratinocytes, but not myeloid cells, endoplasmic reticulum stress
or resveratrol were shown to trigger induction of sphingosine-1-
phosphate, which in turn activates NF-kB–mediated activation of
C/EBP leading to cathelicidin production (48, 49). In human
macrophages activated with dexamethasone, we observed repres-
sion of the NF-kB and NF-kB signaling pathways. This suggests
that the induction of cathelicidin by dexamethasone is not medi-
ated via this pathway in human macrophages. Nevertheless, induction
of cathelicidin by glucocorticoids seems not to be macrophage spe-
cific, because microarray analyses showed that dexamethasone also
triggered cathelicidin gene expression in the human lung A549 cell
line (50).
An important mechanism of phagolysosome maturation and
acidification is the induction of autophagy (7, 8, 35, 36). Con-
sistently, our data showed that inhibition of autophagy by 3-MA
and Wortmannin blunts IFN-g–induced lysosome acidification. In
addition, glucocorticoids reportedly did not trigger autophagy in
M. tuberculosis–infected human monocytic cells (37). In line with
these findings, the green module, correlated to IFN-g stimulation
and inversely correlated with glucocorticoid treatment of macro-
phages, was strongly associated with the IPA biofunctional cate-
gory autophagy. Among autophagy-associated genes in our
analysis of the green module, DRAM1, which has been used as a
marker of autophagy (38), had the highest hierarchical position.
Consistently, IFN-g, but not glucocorticoids, promoted induction
of DRAM1. Recently, DRAM1 was identified as a key host de-
fense gene in antimycobacterial host defense in zebrafish and
human macrophages (33). DRAM1 was found to trigger selective
autophagy downstream of TLR signaling promoting mycobacte-
rial phagosome maturation, phagolysosome fusion, and anti-
mycobacterial activity (33). Knockdown of DRAM1 inhibits the
v-ATPase and acidification of lysosomes (51). Thus, it is tempting
to speculate that DRAM1 links IFN-g induction of autophagy,
TCIRG1, and acidification of lysosomes.
There is a great interest in the biomedical community regarding
the development of host-directed therapies to treat infections. In
TB, for instance, the induction of cathelicidin, autophagy, and
phagosome maturation are potential targets (52). In our study the
ability of imatinib to trigger an antimicrobial response was per-
formed using an avirulent mycobacterium, such that future studies
are required to examine the role of imatinib against virulent
mycobacteria. Nevertheless, imatinib has been demonstrated ef-
fective as a host-directed therapy in a mouse model of TB in-
fection (39, 40) and is currently being developed for a TB clinical
trial (53). Future studies in animal models and clinical trials
should investigate the effectiveness of imatinib in combination
with glucocorticoids in the host-directed treatment of mycobac-
terial infections. This may be particularly useful in the manage-
ment of inflammatory reactions (54–58), including immune
reconstitution inflammatory syndrome, which occurs in HIV/TB-
coinfected individuals at the initiation of chemotherapy and which
is treated with glucocorticoids (59).
FIGURE 8. Imatinib promotes lysosome
acidification and antimycobacterial activity
in dexamethasone (Dexa)-treated human
macrophages. (A and B) MDMs were stim-
ulated with Dexa (100 nM), Imatinib, Dexa
and imatinib in combination, or media alone
for 20 h. Cells were stained with LysoSensor
Green. Acidification was determined by
FACS analyses (% LysoSensor-positive
cells). (A) Histogram plots from one repre-
sentative donor out of seven. (B) Summary of
seven donors (% LysoSensor-positive cells6
SEM, n = 7). (C) Monocytes from patients on
long-term glucocorticoid therapy (GC ther-
apy) were stimulated with imatinib or media
alone for 20 h. Cells were stained with
LysoSensor Green. Acidification was de-
termined by FACS analyses (% LysoSensor-
positive cells 6 SEM, n = 4). (D) MDMs
were infected with BCG for 3–4 h before
stimulation with Dexa (100 nM), Imatinib,
Dexa and imatinib in combination, or media
alone for 3 d. Viable bacteria were quantified
by CFU assay on day 3. Percentage antimi-
crobial activity relative to media (left panel)
and CFU counts (right panel) are shown (6
SEM, n = 5). (E) MDMs were stimulated as
in (A). Cathelicidin mRNA expression was
assessed by quantitative PCR (mean fold
change 6 SEM, n = 6). (F) MDMs were
stimulated as in (A). Pro–IL1-b (n = 5),
TNF-a (n = 5), and IL-10 (n = 5) mRNA
expression were assessed by quantitative
PCR (mean fold change 6 SEM). *p ,
0.05, **p , 0.01.
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Although we demonstrate the role of glucocorticoids in
modulating the innate macrophage antimicrobial response, there
is evidence for immunosuppressive effects on innate instruction
of the adaptive T cell response as well as a direct effect on T cells
(60). In this context, glucocorticoid therapy increases the like-
lihood of false-negative or indeterminate results of the IFN-g
release assay used to diagnose TB in humans (61, 62). Although
our data indicate that imatinib can overcome the deleterious
effects of glucocorticoids on innate antimicrobial responses,
imatinib is also known to suppress adaptive T cell responses
(23). Nevertheless, there are only sporadic reports of infections
in imatinib-treated patients (23). In this regard, our study, by
showing that imatinib promotes lysosome acidification and an-
timicrobial activity in glucocorticoid-stimulated macrophages
without reversing glucocorticoid-mediated anti-inflammatory ef-
fects, suggests one promising strategy to maintain innate antimi-
crobial activity in patients receiving glucocorticoids for treatment
of chronic inflammatory diseases.
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